AstraZeneca partners with CSPC Pharmaceutical Group in a deal worth up to $5.3 billion to develop therapies for chronic conditions using AI-driven research
AstraZeneca and Qure.ai’s AI-enabled chest X-ray program has identified 50,000 individuals at high risk for lung cancer across 20 countries, enhancing early detection in resource-limited settings.
